

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Carton Box

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Bravecto 250 mg spot-on solution for medium-sized cats (>2.8 – 6.25 kg)

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

250 mg fluralaner

3. PACKAGE SIZE

1 x 0.89 ml

2 x 0.89 ml

4. TARGET SPECIES

Cats


5. INDICATION(S)

6. ROUTES OF ADMINISTRATION

Spot-on use.

Read the package leaflet before use.

Cap does not come off.



7. WITHDRAWAL PERIODS

Not applicable.

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Keep the sachet in the outer carton.
Keep the pipette in the sachet until use.
Read the package leaflet before use.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

MSD Animal Health UK Ltd.
Walton Manor, Walton
Milton Keynes
MK7 7AJ

14. MARKETING AUTHORISATION NUMBER

Vm 01708/5022

15. BATCH NUMBER

Lot {number}

16. SPECIAL WARNING(S), IF NECESSARY

Keep the product in the original packaging until use in order to prevent children from getting access to the product. Avoid contact with skin, mouth and/or eye. Do not contact the application site until it is no longer noticeable.
Wear gloves when handling and administering this product. Read package leaflet for full user safety information.

17. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Read the package leaflet before use.

18. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE

POM-V

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

Sachet

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Bravecto 250 mg spot-on solution for medium-sized cats (1.2 – 2.8 kg)

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

250 mg fluralaner


3. TARGET SPECIES

Cats



4. ROUTES OF ADMINISTRATION

For spot-on use



1. Put on gloves. 2. Rotate cap (cap cannot be removed). 3. Apply to skin.

5. WITHDRAWAL PERIODS

Not applicable.

6. EXPIRY DATE

Exp. {mm/yyyy}

7. SPECIAL STORAGE PRECAUTIONS

Keep the sachet in the outer carton.
Keep the pipette in the sachet until use.

8. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

MSD Animal Health UK Ltd.
Walton Manor, Walton
Milton Keynes
MK7 7AJ

9. BATCH NUMBER

Lot {number}

10. PACKAGE SIZE

0.89 ml

11. INDICATION(S)

12. SPECIAL WARNING(S), IF NECESSARY

13. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

14. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE

For animal treatment only.

15. MARKETING AUTHORISATION NUMBER

Vm 01708/5022

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Pipette

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Bravecto

2. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCE(S)

250 mg fluralaner

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

5. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

0.89 ml

6. ROUTE(S) OF ADMINISTRATION

For spot-on use

7. WITHDRAWAL PERIOD

Not applicable

8. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

B. PACKAGE LEAFLET

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Bravecto 112.5 mg spot-on solution for small cats (1.2 – 2.8 kg)
Bravecto 250 mg spot-on solution for medium-sized cats (>2.8 – 6.25 kg)
Bravecto 500 mg spot-on solution for large cats (>6.25 – 12.5 kg)

2. COMPOSITION

Each ml contains 280 mg fluralaner.
Each pipette delivers:

Bravecto spot-on solution	Pipette content (ml)	Fluralaner (mg)
for small cats 1.2 – 2.8 kg	0.4	112.5
for medium-sized cats >2.8 – 6.25 kg	0.89	250
for large cats >6.25 – 12.5 kg	1.79	500

Clear colourless to yellow solution.

3. TARGET SPECIES

Cats.

4. INDICATIONS FOR USE

For the treatment of tick and flea infestations in cats.

This veterinary medicinal product is a systemic insecticide and acaricide that provides immediate and persistent flea (*Ctenocephalides felis*) and tick (*Ixodes ricinus*) killing activity for 12 weeks.

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

For the treatment of infestations with ear mites (*Otodectes cynotis*).

5. CONTRAINDICATIONS

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. SPECIAL WARNING(S)

Special warnings:

Parasites need to start feeding on the host to become exposed to fluralaner; therefore the risk of the transmission of parasite borne diseases cannot be excluded.

Unnecessary use of antiparasitics or use deviating from the instructions given may increase the resistance selection pressure and lead to reduced efficacy. The decision to use the product should be based on confirmation of the parasitic species and burden, or of the risk of infestation based on its epidemiological features, for each individual animal.

The possibility that other animals in the same household can be a source of re-infection with parasites should be considered, and these should be treated as necessary with an appropriate product.

Special precautions for safe use in the target species:

Care should be taken to avoid contact with the eyes of the animal. Do not use directly on skin lesions.

In the absence of available data, this veterinary medicinal product should not be used on kittens less than 9 weeks old and /or cats weighing less than 1.2 kg.

The product should not be administered at intervals shorter than 8 weeks as the safety at shorter intervals has not been tested.

This product is for topical use and should not be administered orally.

Do not allow recently treated animals to groom each other.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Contact with the product should be avoided and disposable protective gloves obtained with this product at the point of sale must be worn when handling the product for the following reasons:

Hypersensitivity reactions have been reported in a small number of people, which can potentially be serious.

Persons with a hypersensitivity to fluralaner or to any of the excipients should avoid any exposure to the product.

The product binds to skin and may also bind to surfaces after spillage of the product.

Skin rashes, tingling or numbness have been reported in a small number of individuals after skin contact.

If skin contact does occur, wash the affected area immediately with soap and water.

In some cases, soap and water are not sufficient to remove the product spilled on the fingers.

Contact with the product may also occur when handling the treated animal.

Make sure that your animal's application site is no longer noticeable before resuming contact with the site of application. This includes cuddling the animal and sharing a bed with the animal. It takes up to 48 hours for the application site to become dry but it will be noticeable for longer.

If skin reactions occur, consult a physician and show them the product packaging.

People with a sensitive skin or known allergy in general e.g. to other veterinary medicinal products of this type should handle the veterinary medicinal product as well as treated animals with caution.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

This product is harmful after ingestion. Keep the product in the original packaging until use, in order to prevent children from getting direct access to the product. A used pipette should immediately be disposed of. In case of accidental ingestion, seek medical advice and show the package leaflet or the label to the physician.

The product is highly flammable. Keep away from heat, sparks, open flame or other sources of ignition. In case of spillage onto, for example table or floor surfaces, remove excess product using paper tissue and clean the area with detergent.

Pregnancy, lactation and fertility:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only accordingly to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

None known.

Fluralaner is highly bound to plasma proteins and might compete with other highly bound active substances such as non-steroidal anti-inflammatory drugs (NSAIDs) and the coumarin derivative warfarin. Incubation of fluralaner in the presence of carprofen or warfarin in dog plasma at maximum expected plasma concentrations did not reduce the protein binding of fluralaner, carprofen or warfarin.

During laboratory and clinical field testing, no interactions between Bravecto spot-on solution for cats and routinely used veterinary medicinal products were observed.

Overdose:

Safety was demonstrated in kittens aged 9 - 13 weeks and weighing 0.9 - 1.9 kg treated with overdoses of up to 5 times the maximum recommended dose on three occasions at shorter intervals than recommended (8-week intervals).

Oral uptake of the product at the maximum recommended dose was well tolerated in cats, apart from some self-limiting salivation and coughing or vomiting immediately after administration.

Major incompatibilities:

None known.

7. ADVERSE EVENTS

Cats:

Common (1 to 10 animals / 100 animals treated):	Skin reactions at the application site (Erythema, Pruritus, Alopecia)*#
Uncommon (1 to 10 animals / 1,000 animals treated):	Muscle tremor*, Lethargy*, Anorexia*, Emesis*, Hypersalivation*
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Convulsion**

* observed in clinical trials

** reported during post marketing safety experience, self-limiting and of short duration

mild and transient

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For spot-on use.

The veterinary medicinal product should be administered in accordance with the following table (corresponding to a dose of 40 – 94 mg fluralaner/kg body weight):

Body weight of cat (kg)	Strength and number of pipettes to be administered		
	Bravecto 112.5 mg	Bravecto 250 mg	Bravecto 500 mg
1.2 – 2.8	1		
>2.8 – 6.25		1	
>6.25 – 12.5			1


For cats above 12.5 kg body weight, use a combination of two pipettes that most closely matches the body weight.

Underdosing could result in ineffective use and may favour resistance development.


9. ADVICE ON CORRECT ADMINISTRATION

Method of administration

Step 1: Immediately before use, open the sachet and remove the pipette. Put on gloves. The pipette should be held by the base or by the upper rigid portion below the cap in an upright position (tip up) for opening it. The twist-and-use cap should be rotated clockwise or counter clockwise one full turn. The cap will stay on the pipette; it is not possible to remove it. The pipette is open and ready for application when the breaking of the seal is felt.



Step 2: The cat should be standing or lying with its back horizontal for easy application. Place the pipette tip on the base of the skull of the cat.



Step 3: Squeeze the pipette gently and apply the entire contents directly to the cat's skin. The product should be applied on cats up to 6.25 kg body weight in one spot at the base of the skull and in two spots on cats greater than 6.25 kg body weight.

Treatment schedule

For optimal control of tick and flea infestation, the product should be administered at intervals of 12 weeks.

For the treatment of ear mite infestations (*Otodectes cynotis*), a single dose of the product should be applied. A further veterinary examination 28 days after treatment is recommended as some animals may require further treatment with an alternative product.

10. WITHDRAWAL PERIOD(S)

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special temperature storage conditions.

The pipettes should be kept in the outer packaging to prevent solvent loss or moisture uptake.

The sachets should only be opened immediately prior to use.

Do not use this veterinary medicinal product after the expiry date stated on the packaging after Exp. The expiry date refers to the last day of that month.

12. SPECIAL PRECAUTIONS FOR DISPOSAL

Medicines should not be disposed of via wastewater.

The veterinary medicinal product should not enter water courses as fluralaner may be dangerous for aquatic invertebrates.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

Joint labelling with central marketing authorisations will only include the following wording:

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

13. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 01708/5017	112.5 mg
Vm 01708/5022	250 mg
Vm 01708/5025	500 mg

Each cardboard box contains 1 or 2 pipettes and a pair of gloves per pipette.
Not all pack sizes may be marketed.

15. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST REVISED

May 2023

Find more product information by searching for the Product Information Database 'PID' on www.gov.uk.

16. CONTACT DETAILS

Marketing authorisation holder:

MSD Animal Health UK Ltd.
Walton Manor, Walton
Milton Keynes
Buckinghamshire
MK7 7AJ

Manufacturer responsible for batch release:

Intervet Productions
Rue de Lyons
27460 Igoville
France

Contact details to report suspected adverse reactions:

MSD Animal Health UK Ltd.
Tel.: +44 (0)1908 685685

17. OTHER INFORMATION

The product contributes towards the control of environmental flea populations in areas to which treated cats have access.
The onset of efficacy is within 12 hours for fleas (*C. felis*) and within 48 hours for ticks (*I. ricinus*).

For animal treatment only.

POM-V To be supplied only on veterinary prescription.

Approved 24 January 2024

Revised: January 2024
AN: 02555/2022

A handwritten signature in black ink, consisting of a stylized initial 'A' followed by the name 'Hunter.' with a period.